I had no idea what check logs were, but I found more information in Edible Forest Gardens as well as in Rainwater Harvesting for Drylands and Beyond, where they are referred to as check dams. I sought council from local permaculture practitioners, who suggested that I look into the concept of check logs. Oh, and the solution needed to be cheap and low tech, because after all, we’re just a volunteer group operating on a small budget. We were looking for a garden terrace solution that not only helped stabilize the hillside, but also helped increase fertility (to make up for all that had washed away). Any topsoil and nutrients that may have been there at one time had since washed away. The hillside was prone to land-sliding and erosion. In 2011, I started Hillside Community Garden, and as the name implies, we had a steep challenge. Oh, and don’t forget to grab your FREE DOWNLOAD: Building a Check Log Terrace Quick Start Guide at the end of the article. The company earlier on Monday announced a partnership with Ionis Pharmaceuticals Inc (IONS.O) to develop and commercialize a therapy for antisense oligonucleotide (ASO), a rare, severe chronic kidney disease.Are you challenged with sloping land? Here’s a solution to stop erosion on a hillside and create an easily-navigable terrace garden. There was no immediate comment from Seattle-based Chinook. The firm has a "buy" recommendation and a price target of $51 on the stock. Previously, Bloom Burton had said previously there was a 70% probability the FDA approves Chinook's atrasentan. Antonia Borovina, an analyst at Bloom Burton Securities in Toronto, declined to comment as she had not yet fully read the Muddy Waters report. There are six analysts with "buy" recommendations for Chinook, according to Refinitiv data. Muddy Waters said Chinook's drug atrasentan has been shown to be harmful to patients’ cardiovascular health and that is was not producing the desired effect on chronic kidney disease. But immediately after Muddy Waters announced its short position, a bet the stock would decline, Chinook shares fell as low as $19.20, down 18% from the $23.40 close on Monday. The stock was last down 6.77% at $21.815 a share. LONDON, May 16 (Reuters) - Shares of Chinook Therapeutics Inc (KDNY.O) tumbled 18% and then pared losses on Tuesday after short-seller Muddy Waters said it was "highly unlikely" that the company's treatment for chronic kidney disease would receive U.S.
0 kommentar(er)
